We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Practice Gaps |

The Need to Examine the Risks and Benefits of Intravenous Immunoglobulin Therapy in Severe Cutaneous Adverse Reactions  Comment on “Poor Benefit/Risk Balance of Intravenous Immunoglobulins in DRESS”

Cindy England Owen, MD
Arch Dermatol. 2012;148(4):545. doi:10.1001/archdermatol.2011.3156.
Text Size: A A A
Published online


Severe cutaneous adverse reactions (SCARs) include drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). These reactions are rare but serious, with mortality ranging up to 10% in DRESS and as high as 30% in TEN. Despite the seriousness of SCARs, there is a lack of evidence-based consensus on treatment for these conditions.

Since Viard et al1 showed success with intravenous immunoglobulin therapy (IVIG) in 10 patients with TEN,1 IVIG has become commonly prescribed for this condition. While DRESS is most often treated with systemic steroids, Joly et al describe a reasonable hypothesis for the use of IVIG in this condition. In the trial, however, treatment with IVIG demonstrated a poor benefit/risk ratio, with 5 of 6 patients experiencing an adverse reaction, and only 1 complete and 1 partial response. Based on this small study, IVIG should be avoided in DRESS, pending further research.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles